Published by Josh White on 6th April 2021
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.
URL: http://www.digitallook.com/dl/news/story/31753387/...